Partnerships
Partner with us
We collaborate with businesses and institutions to develop advanced in vitro models using our proprietary technology and scientific expertise. Our assistance is tailored to your needs, and ranges from providing you with platforms and technical support, to the development and validation of customised models. Contact us to know more.
Some of our partners
Case study #1: University of Ferrara
Status: ongoing
We are collaborating to develop complex in vitro models of the central nervous system including both the blood-brain barrier and the blood-cerebrospinal fluid barrier.
Poster
Eugenol induced dopamine release from neuron-like PC12 cells after its permeation across the physiological brain barriers simulated in a new organ-on-a-chip platform
Pavan et. al., 2023
This study explores Eugenol's neuropharmacological properties using the CELLBLOKS® organ-on-a-chip platform, allowing the simulation of multiple physiological barriers within one system. The models include human cerebral microvascular endothelial cells (hCMEC/D3) representing the BBB, Human Retinal Pigment Epithelial (HRPE) cells as a BCSFB model, and Rat small Intestinal Epithelial cells (IEC-6) mimicking the GI barrier. The research examines Eugenol's ability to induce dopamine release in neuron-like PC12 cells grown in NANOSTACKSTM inserts.The findings extend beyond neuropharmacology, offering insights into Eugenol's interactions with these barriers. This research may have broader therapeutic implications, with the potential to impact various strategies. Presented at the 73rd SIF National Congress, this study marks a significant step in understanding Eugenol's pharmacology and its passage through physiological barriers
DOWNLOAD
Case study #2: University of Sheffield
Status: ongoing
This collaboration focuses on the development of in vitro models of head and neck cancer, to improve our understanding of the tumour microenvironment.
Application Note
Development of Accurate 3D Models of Head and Neck Cancer Using Revivocell's NANOSTACKSTM Platform
Khurram et al.,2023; School of Clinical Dentistry at The University of Sheffield, United Kingdom
In the proof of concept study conducted by Prof. Ali Khurram and his team from the School of Clinical Dentistry at The University of Sheffield, United Kingdom, they utilized cancer cells from the primary site of head and neck cancer, cancer cells from the metastasis site from the same patient, and normal fibroblasts. By incorporating these cell types into Revivocell's NANOSTACKSTM platform, the researchers aimed to develop accurate 3D models that mimic the tumor microenvironment and enable a better understanding of head and neck cancer progression and metastasis. This preliminary work, published by Prof. Ali Khurram et al., highlights the potential of Revivocell's technology for advanced cancer research and sets the stage for further investigations into therapeutic interventions.
DOWNLOAD
Need some help?
If you're interested in discovering how our organ models can benefit your research, we invite you to get in touch with us. Our team is available to provide further insights and address any inquiries you may have.
Contact information
UK
USA
BioLabs@NYU LANGONE, 180 Varick St, Floor 6, New York, NY 10014
info@revivocell.com
Revivocell Brands
